Madrigal Pharmaceuticals (MIL:1MDGL) Total Operating Expense: €1,174.5 Mil (TTM As of Mar. 2026)


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €460.60
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Total Operating Expense?

Madrigal Pharmaceuticals MIL:1MDGL 8 Total Operating Expense is €1,174.5 Mil as of Mar. 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Madrigal Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was €326.3 Mil. Madrigal Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €1,174.5 Mil.

Madrigal Pharmaceuticals Total Operating Expense Related Terms

Madrigal Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals Total Operating Expense Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 214.60 277.13 348.92 641.55 1,026.81

Madrigal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.15 217.56 326.42 304.23 326.29
MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,174.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €1,174.5 Mil mean?
Madrigal Pharmaceuticals (MIL:1MDGL) has a Total Operating Expense of €1,174.5 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' Total Operating Expense too high?
Madrigal Pharmaceuticals' current Total Operating Expense is €1,174.5 Mil. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Total Operating Expense compare to BMRN and AXSM?
Madrigal Pharmaceuticals' Total Operating Expense of €1,174.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Total Operating Expense is €1,174.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Total Operating Expense of €1,174.5 Mil. The current Total Operating Expense is €1,174.5 Mil. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Total Operating Expense is €1,174.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€460.60
Price